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for 2 atopic individuals with CAP class 1 to marijuana and 1 
other atopic individual with CAP class 1 to hashish. Stimula-
tion of basophils with hashish or marijuana extracts elicited 
histamine release from basophils of both patients and 4 
atopic control subjects.  Conclusions: Our results suggest an 
IgE-related pathomechanism for hypersensitivity reactions 
to marijuana or hashish.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Different subspecies of hemp  (Cannabis) have been 
cultivated for the production of fibers  (C. sativa sativa) 
or hallucinogenic drugs such as hashish or marijuana. 
While hashish is derived from the compressed stalked 
resin glands of the  Cannabis plant, called trichomes, the 
term marijuana refers to the whole dried leaves and flow-
ers  [1] . When female plants are grown isolated from male 
plants to avoid pollination (so-called sinsemilla), they 
produce particularly large amounts of the hallucinogen 
tetrahydrocannabinol. Despite the immense popularity 
of cannabis-derived psychoactive drugs around the 
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 Abstract 
 Background: There have been sporadic reports of hyper-
sensitivity reactions to plants of the Cannabinaceae family 
(hemp and hops), but it has remained unclear whether these 
reactions are immunologic or nonimmunologic in nature. 
 Objective: We examined the IgE-binding and histamine- 
releasing properties of hashish and marijuana extracts by 
CAP-FEIA and a basophil histamine release test.  Methods: 
Two workers at a forensic laboratory suffered from nasal con-
gestion, rhinitis, sneezing and asthmatic symptoms upon
occupational contact with hashish or marijuana, which they 
had handled frequently for 25 and 16 years, respectively. Nei-
ther patient had a history of atopic disease. Serum was ana-
lyzed for specific IgE antibodies to hashish or marijuana ex-
tract by research prototype ImmunoCAP, and histamine re-
lease from basophils upon exposure to hashish or marijuana 
extracts was assessed. Results were matched to those of 4 
nonatopic and 10 atopic control subjects with no known his-
tory of recreational or occupational exposure to marijuana 
or hashish.  Results: Patient 1 had specific IgE to both hashish 
and marijuana (CAP class 2), and patient 2 to marijuana only 
(CAP class 2). Controls proved negative for specific IgE except 
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world, there have been only sporadic reports of hypersen-
sitivity reactions to plants of the Cannabinaceae family 
 [2–11] . Here, we report 2 further patients with cannabis 
allergy due to occupational allergen exposure. 
 Patients and Methods 
 Patients 
 A 52-year-old female technician (patient 1) working at a foren-
sic laboratory had a 25-year history of occupational contact with 
cannabis products, but no recreational exposure. For 4 years she 
had been suffering from nasal congestion, sneezing and dyshi-
drotic hand eczema when handling hashish or marijuana, par-
ticularly the sinsemilla variant. A 49-year-old male physician (pa-
tient 2) working at the same institution had been handling can-
nabis products for 16 years. Recreational exposure was denied. 
For 8 years he had complained of nasal congestion, sneezing and 
occasionally mild asthma while working in the room where court 
exhibits were kept. Neither patient had a history of atopic disease.
 Standard Tests  
 Specific IgE antibodies to various common aeroallergens 
(grass, mugwort and birch pollen) and total IgE were measured 
by UniCAP (Phadia, Freiburg, Germany). 
 Cannabis-Specific IgE 
 For measurement of specific IgE antibodies to hashish or mar-
ijuana, hashish and marijuana were extracted in saline, and an 
amount equaling 1 mg of protein was biotinylated (Biotin Label-
ing Kit, Roche Diagnostics) and coupled to streptavidin-CAPs 
(Phadia) according to the manufacturer’s instructions. 
 Histamine Release Assay 
 For histamine release testing, hashish and marijuana were ex-
tracted in saline. After centrifugation, the supernatant was ad-
justed to 1 mg of protein/ml and added to peripheral blood mono-
nuclear cells prestimulated with IL-3 as described elsewhere  [12] . 
Histamine release from basophils upon exposure to the extracts 
was analyzed using an Autoanalyzer II (Bran und Lübbe). Baso-
phil histamine content was measured spectrofluorometrically af-
ter cell fragmentation, and absolute histamine release into the su-
pernatant was determined with and without IL-3 stimulation. 
 Controls  
 Results were matched to those of 4 nonatopic and 8 atopic con-
trol subjects. Individuals were classified as atopic when skin prick 
test reactions to common aeroallergens (cat dander, house dust 
mite and/or grass pollen) were positive or when the patient re-
ported a history of hay fever, asthma or atopic eczema. Individuals 
were considered nonatopic when they had neither a history of hay 
fever, asthma or atopic eczema, nor skin prick test reactions to the 
aeroallergens mentioned. Controls denied recreational or occu-
pational exposure to marijuana or hashish.
 Skin prick tests for marijuana or hashish were not performed 
because of legal constraints. The license to handle cannabis prod-
ucts was granted exclusively for testing in vitro. No use on human 
subjects was allowed.
 Results 
 Specific IgE antibodies were demonstrable in the se-
rum of patient 1 to both hashish (2.82 kU/l; CAP class 2) 
and marijuana (0.72 kU/l; CAP class 2), and in the serum 
of patient 2 to marijuana only (0.86 kU/l; CAP class 2). 
Controls proved negative for marijuana- or hashish-spe-
cific IgE except for 2 atopic individuals to marijuana (0.38 
and 0.68 kU/l, respectively; CAP class 1) and 1 atopic in-
dividual to hashish (0.5 kU/l; CAP class 1;  fig. 1 a).
 Histamine release was triggered by hashish and mari-
juana extracts in both patients and 4 control subjects 
( fig. 1 b). There was no association between specific IgE 
levels and atopic disease.
 Discussion 
 Immediate-type allergy to marijuana or hashish has 
rarely been documented. Three previously reported cases 
from Europe were also related to handling of hashish or 
marijuana in forensic laboratories  [6, 7, 11] . Two more 
cases were connected to the recreational consumption of 
marijuana  [3, 13] . A further report described a Califor-
nian patient who developed a severe anaphylactic reac-
tion following the intravenous administration of a mari-
juana concoction  [9] . Urticaria, facial angioedema and 
dyspnea after the ingestion of hemp-seed-crusted food in 
a restaurant have also been observed  [2] . The scarcity of 
documented allergic reactions related to recreational 
 Cannabis consumption may simply reflect underreport-
ing of complaints by patients due to the illegal nature of 
the use of the drug in most countries. It is said that mar-
ijuana smokers frequently get red eyes while smoking. 
Still, it has remained unclear whether these reactions are 
immunologic or nonimmunologic in nature.
 However, cannabis products seem to act as allergens 
which are also recognized by IgE antibodies of atopic 
controls who had not knowingly been exposed to canna-
bis. We do not know the reason for this probable cross-
reactivity.  Cannabis pollen is still not common in south-
ern Germany. Corresponding sensitization is predomi-
nantly found in regions where cultivation of  Cannabis 
plants is common, such as in south- and midwestern
USA and central India  [4, 14, 15] . However, it is unclear 
to which degree sensitization to cannabis pollen corre-
sponds to clinical symptoms upon exposure to hashish
or   marijuana.   Rather   than   from   contact   to   hemp   pol-
len, sensitization may also have developed through con-
tact with nonhallucinogenic hemp products. Such hemp 
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products are fairly common in textiles/fibers or foods (ce-
reals, bird seed). Another possible reason for elevated IgE 
may be cross-reactivity with cross-reacting carbohydrate 
determinants.
 Another putative reason for the reactivity of the sera 
could have been contamination of the cannabis speci-
mens used for the CAP or histamine release assays by 
mold allergens. However, the sera of neither patient con-
tained specific IgE to  Aspergillus fumigatus, Cladospori-
um herbarum or  Alternaria alternata , making mold con-
taminants an unlikely source of the reactivity of the sera.
 Sensitization to marijuana and/or hashish was reflect-
ed by demonstrable levels of specific IgE antibodies and 
allergen-induced release of histamine from basophils in 
our patients, showing that hypersensitivity to hashish 
and marijuana is immunologic in nature. We did not 
identify the immunogenic component of  Cannabis trig-
gering the response in our patients. However, it seems 
unlikely that  Cannabis pollen contained the allergen in 
patient 1 since she reported the most severe reactions 
upon contact to sinsemilla, i.e. female  Cannabis plants 
that are not allowed to be pollinated in order to maximize 
production of the hallucinogen tetrahydrocannabinol.
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 Fig. 1.  a Levels of specific IgE to hashish or 
marijuana extracts in patients (P) and 8 
atopic (AC) and 4 nonatopic (NAC) con-
trols.  b Histamine release from basophils 
from the same patients and controls as in 
 a was analyzed following incubation with 
hashish or marijuana extracts. 
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